Lose Weight, Escape the Eight: Weight-Based Cancer Risk
News Aug 26, 2016
A new evaluation carried out by the IARC Handbooks of Cancer Prevention programme has concluded that overweight/ obesity is a risk factor for more cancer sites than previously established. These findings are based on a systematic review of the published scientific literature, the Working Group for IARC Handbooks of Cancer Prevention Volume 16: Body Fatness provided the latest evaluation of the cancer-preventive effects of the absence of excess body fatness. A summary of the results is published today in The New England Journal of Medicine.
A Working Group of 21 independent international experts, convened by the International Agency for Research on Cancer (IARC), assessed more than 1000 studies, including intervention trials, cohort and case –control studies, studies in experimental animals, and studies on the mechanisms linking excess body fatness and cancer. “This comprehensive evaluation reinforces the benefits of maintaining a healthy body weight in order to reduce the risk of several different types of cancer,” says Dr Béatrice Lauby-Secretan, lead author of the new article.
Link between overweight/obesity and cancer
The experts confirmed the previous evaluation of the IARC Handbooks (Volume 6, published in 2002) that the absence of excess body fatness reduces the risk of cancer s of the colon and rectum, oesophagus (adenocarcinoma), kidney (renal cell carcinoma), breast in postmenopausal women, and endometrium of the uterus.
In addition, the review of the available literature for middle-aged adults showed that there is sufficient evidence in humans that the absence of excess body fatness reduces the risk of cancers of the gastric cardia, liver, gallbladder, pancreas, ovary, and thyroid, and meningioma, and multiple myeloma. There is also limited evidence that the absences of excess body fatness reduces the risk of fatal cancer of the prostate, cancer of the breast in men, and diffuse large B-cell lymphoma.
The Working Group al so reviewed data pertaining to body fatness in children, adolescents, and young adults (aged up to 25 years) to assess whether obesity at earlier periods of life is linked with cancer in adult life. For several cancer sites, including the colon and the liver, associations between excess body weight and cancers were observed that were similar to those reported in adults.
It is well established that overweight in experimental animals increases the incidence of several types of cancer. Studies in overweight animals showed that caloric or dietary restriction reduces the risk of cancers of the mammary gland, colon, liver, pancreas, skin, and pituitary gland.
Global burden of overweight and obesity
Body fatness is assessed primarily by body mass index (BMI), defined as a person’s weight in kilograms divided by the square of their height in metres (kg/m2). In adults, overweight is defined as BMI ≥ 25 kg/m2, and obesity as BMI ≥ 30 kg/m2. Worldwide, an estimated 640 million adults were obese in 2014 (a 6-fold increase since 1975) and 110 million children and adolescents were obese in 2013 (a 2-fold increase since 1980). The estimated age-standardized prevalence of obesity in 2014 was 10.8% in men, 14.9% in women, and 5.0% in children, and globally more people are overweight or obese than are underweight.
In 2013, an estimated 4.5 million deaths worldwide were attributable to overweight and obesity. The identification of new obesity-related cancer sites will add to the number of deaths worldwide attributable to obesity.
“The new evidence emphasizes how important it is to find effective ways, at both the individual and societal level, to implement World Health Organization recommendations on improving diets and physical activity patterns throughout life if the burden of cancer and other non-communicable diseases is to be tackled,” says IARC Director Dr Christopher Wild.
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE
Comments | 0 ADD COMMENT
International Conference on Central Nervous System and Therapeutics
Nov 12 - Nov 14, 2018